COMMUNIQUÉS West-GlobeNewswire

-
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
31/07/2025 -
Kura Oncology to Report Second Quarter 2025 Financial Results
31/07/2025 -
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
31/07/2025 -
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
31/07/2025 -
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
31/07/2025 -
VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration
31/07/2025 -
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
31/07/2025 -
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
31/07/2025 -
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results
31/07/2025 -
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7
31/07/2025 -
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
31/07/2025 -
Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award
31/07/2025 -
PL BioScience Announces Major Site Expansion
31/07/2025 -
VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration
31/07/2025 -
Ipsen publie de solides résultats au premier semestre 2025 et relève ses objectifs financiers annuels
31/07/2025 -
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
31/07/2025 -
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
31/07/2025 -
Pharming Group reports second quarter and first half 2025 financial results and provides business update
31/07/2025 -
Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025
31/07/2025
Pages